Perspectives for yttrium-90 radioembolization as therapeutic option for hepatocellular carcinoma

Marta Burrel,Patricia Bermúdez, Alejandro Forner González

REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS（2022）

Cited 0|Views7

No score

Abstract

The therapeutic management of hepatocellular carcinoma (HCC) has achieved great advances in the past few years. Before the publication of the SHARP clinical trial, which showed the effectiveness of sorafenib in patients with advanced HCC, no effective systemic therapy was available and only transarterial chemoembolization (TACE) had shown an impact on survival in clinical trials.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined